Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias (RUBY-4)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507067-19-00

Acronym

AIS-D04

Enrollment

Registered

2024-04-15

Start date

2024-05-15

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Cytopenias (warm autoimmune hemolytic anemia [wAIHA], cold agglutinin disease [CAD], immune thrombocytopenia [ITP])

Brief summary

Type, incidence, severity, and seriousness of AEs.

Detailed description

Assessment of efficacy, PK, and ADA

Interventions

DRUGPovetacicept Injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Type, incidence, severity, and seriousness of AEs.	—

Secondary

Measure	Time frame
Assessment of efficacy, PK, and ADA	—

Countries

Austria, Germany, Italy, Norway, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026